Immunome Inc. (IMNM)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Immunome Inc. reported revenue of $6.94M, down 23.2% from the prior year. The company ran a net loss, with a net margin of -3060.0%. It held $683.19M in total assets against $48.84M in total liabilities.
Key ratios (FY2025)
-3228.8%
Operating margin
-3060.0%
Net margin
-33.5%
Return on equity
-23.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.94M | $9.04M | $14.02M | — | — | — | — | — |
| Operating Income | -$224.11M | -$305.80M | -$109.53M | -$36.90M | -$25.20M | -$12.26M | -$10.35M | — |
| Net Income | -$212.39M | -$292.96M | -$106.81M | -$36.90M | -$24.71M | -$17.84M | -$10.44M | — |
| EPS (Diluted) | $-2.43 | $-5.00 | $-5.38 | $-3.09 | $-2.14 | $-5.26 | — | — |
| Total Assets | $683.19M | $240.24M | $148.54M | $24.05M | $57.92M | $44.52M | $5.06M | — |
| Total Liabilities | $48.84M | $59.08M | $28.66M | $7.39M | $9.74M | $3.18M | $1.80M | — |
| Shareholders' Equity | $634.34M | $181.16M | $119.88M | $16.65M | $48.19M | $41.34M | -$35.63M | -$25.20M |
| Cash & Equivalents | $653.48M | $143.35M | $98.68M | $20.32M | $49.23M | $39.77M | $2.54M | — |
| Operating Cash Flow | -$190.92M | -$110.79M | -$7.57M | -$28.69M | -$18.23M | -$12.13M | -$9.60M | — |
| Capital Expenditures | $9.69M | $7.17M | $831.0K | $248.0K | $79.0K | $586.0K | $233.0K | — |
| Shares Outstanding | 113.13M | 64.46M | 43.25M | 12.13M | 12.11M | 10.63M | 1.10M | — |